Skip to main content
. 2023 Nov 14;13:1283951. doi: 10.3389/fonc.2023.1283951

Table 3.

Synergy between MEN1611 and gefitinib in NSCLC cell lines.

Drug RA1 RA2 RB1
Dm (µM) Gef > 10 > 10 > 10
MEN1611 4.9 –7.2 2.5 –5.9 5.5 – 10.0
Gef+MEN1611 1.1 –1.9 1.9 –4.9 3.5 – 6.1
CI Gef+MEN1611 0.1 –0.2 0.2 –0.4 0.2 – 0.4

Median-effect dose (Dm) of single and combination drugs and relative combination index (CI) of EGFR-TKi resistant NSCLC cell lines, calculated at 50% of fraction affected. Gefitinib, Gef.